The indications and donor-site morbidity of tibial cortical strut autografts in the management of defects in long bones.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 29701102.
- Also identified by DOI 10.1302/0301-620X.100B5.BJJ-2017-0577.R2.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The primary aim of this study was to determine the morbidity of a tibial strut autograft and characterize the rate of bony union following its use. We retrospectively assessed a series of 104 patients from a single centre who were treated with a tibial strut autograft of > 5 cm in length. A total of 30 had a segmental reconstruction with continuity of bone, 27 had a segmental reconstruction without continuity of bone, 29 had an arthrodesis and 18 had a nonunion. Donor-site morbidity was defined as any event that required a modification of the postoperative management. Union was assessed clinically and radiologically at a median of 36 months (IQR, 14 to 74). Donor-site morbidity occurred in four patients (4%; 95% confidence interval (CI) 1 to 10). One patient had a stress fracture of the tibia, which healed with a varus deformity, requiring an osteotomy. Two patients required evacuation of a haematoma and one developed anterior compartment syndrome which required fasciotomies. The cumulative probability of union was 90% (95% CI 80 to 96) at five years. The type of reconstruction (p = 0.018), continuity of bone (p = 0.006) and length of tibial graft (p = 0.037) were associated with the time to union. The tibial strut autograft has a low risk of morbidity and provides adequate bone stock for treating various defects of long bones. Cite this article: Bone Joint J 2018;100-B:667-74.
Medical subject headings
- Bone Diseases
- Bone Transplantation
- Tibia
- Transplant Donor Site
- Wounds and Injuries
Anatomy
- tibia